1 September 2025
\n \n \n \nCollaboration leverages OMass\u2019 OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.
\n \n\n \n \n25 August 2025
\n \n \n \nOXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.
\n \n\n \n \n21 August 2025
\n \n \n \nInfinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.
\n \n\n \n \n19 August 2025
\n \n \n \nWe\u2019re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.
\n \n\n \n \n19 August 2025
\n \n \n \nIcosphere Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Develop Breakthrough Gene Therapy Vector Manufacturing Technology.
\n \n\n \n \n6 August 2025
\n \n \n \nTheolytics has created an extensive proprietary library of oncolytic viruses (viruses that kill cancer cells) to harness their potential to safely target and destroy tumour cells while leaving healthy cells intact.
\n \n\n \n \n6 August 2025
\n \n \n \nInfinitopes received Innovate UK funding through the Investor Partnership Programme, which was pivotal to building and testing their cutting-edge discovery platform, and the Cancer Therapeutics Programme, to design, prepare and execute its phase I clinical trial, that scientists hope will be practice-changing.
\n \n\n \n \n5 August 2025
\n \n \n \nOMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.
\n \n\n \n \n30 July 2025
\n \n \n \nIt was an afternoon of high drama as BioEscalator tenants took to the floor in our recent annual Pitch Battle to compete for the Best Pitch prize, sponsored by Oxford North, and a range of other accolades.
\n \n\n \n \n27 July 2025
\n \n \n \nU-Ploid Biotechnologies is rewriting the script on fertility treatments, tackling the root cause of age-related egg decline with groundbreaking science.
\n \n\n \n \n23 July 2025
\n \n \n \nWho knew? Young adults do listen to their parents, and the BioEscalator is very glad about that. Becson Ody, our first Business Administration & Reception apprentice, found out about apprenticeships through his father, who is a \u2018big advocate\u2019.
\n \n\n \n \n20 July 2025
\n \n \n \nJLL announced today that it has completed a sublease for growing U.K.-based biotech company Ochre Bio at 430 East 29th St. within the Alexandria Center\u00ae for Life Science \u2013 New York City.
\n \n\n \n \n13 July 2025
\n \n \n \nOMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces positive preclinical data for OMS1620, its lead program targeting the melanocortin-2 (MC2) receptor, at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July.
\n \n\n \n \n1 July 2025
\n \n \n \nThe BioEscalator is very proud to be home to a stellar collection of companies using cutting-edge science to tackle profound medical challenges. Our new Portfolio 2025 brings them together to showcase their innovative approaches and provide a valuable guide for potential investors and partners.
\n \n\n \n \n29 June 2025
\n \n \n \nOxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO.
\n \n\n \n \n4 June 2025
\n \n \n \nStay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Summer 2025 edition of the BioEscalator Bulletin.
\n \n\n \n \n28 May 2025
\n \n \n \nThe appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics.
\n \n\n \n \n27 May 2025
\n \n \n \nPGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs. PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild. DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.
\n \n\n \n \n26 May 2025
\n \n \n \nNucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology\r\ncompany harnessing the power of non-coding human genetics to discover first-in-class antibody\r\ntreatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business\r\nOfficer with immediate effect.
\n \n\n \n \n22 May 2025
\n \n \n \nWe are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.
\n \n\n \n \n